Charles Zhu
Stock Analyst at Guggenheim
(3.39)
# 768
Out of 4,667 analysts
23
Total ratings
52.38%
Success rate
18.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $4.08 | +96.08% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.28 | +265.85% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $42.93 | +11.81% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $91.17 | -38.58% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $2.31 | +852.38% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $9.08 | +186.34% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $25.54 | +25.29% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $14.55 | -3.78% | 2 | May 5, 2022 |
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $4.08
Upside: +96.08%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.28
Upside: +265.85%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $42.93
Upside: +11.81%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $91.17
Upside: -38.58%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $2.31
Upside: +852.38%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $9.08
Upside: +186.34%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $25.54
Upside: +25.29%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $14.55
Upside: -3.78%